General Information of Drug Transporter (DT)
DT ID DTD0394 Transporter Info
Gene Name SLC52A2
Transporter Name Riboflavin transporter 3
Gene ID
79581
UniProt ID
Q9HAB3
Post-Translational Modification of This DT
Overview ofSLC52A2 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-Phosphorylation X-Phosphorylation X-SUMOylation X-Ubiquitination X: Amino Acid

Phosphorylation

  Serine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC52A2 [1]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

273

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC52A2 Serine 273 has the potential to affect its expression or activity.

  Tyrosine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

. [2]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

305

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC52A2 Tyrosine 305 has the potential to affect its expression or activity.

SUMOylation

  Lysine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

. [3]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

267

Experimental Method

Co-Immunoprecipitation

Detailed Description

SUMOylation at SLC52A2 Lysine 267 has the potential to affect its expression or activity.

Ubiquitination

  Lysine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

. [3]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

75

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC52A2 Lysine 75 has the potential to affect its expression or activity.
References
1 Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
2 15 years of PhosphoSitePlus?: integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 2019;47(D1):D433-D441.
3 ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. Nucleic Acids Res. 2018;46(D1):D901-D910.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.